Disabling foot pain and its impact on daily living among people with psoriatic arthritis in Singapore: a cross-sectional observational investigation

Table 2 Global disease measures and disease indices of participants with and without disabling foot pain (DFP) in PsA

	Total n = 42	with DFP n = 17	without DFP n = 25	p-value
MD-HAQ (median, IQR)	0.3 (0.6)	0.5 (0.7)	0.2 (0.5)	0.03*
Global Pain (NRS 0–10) (median, IQR)	3 (4)	4 (2)	2 (4)	0.009*
Patient Global Assessment (NRS 0–10) (median, IQR)	3 (4)	5 (2)	2 (5)	0.006*
Physician Global Assessment (VAS 0–100 mm)⁺ (mean, SD)	26 (20)	36 (24)	21 (15)	0.048*
RAPID3 (mean, SD)	7.5 (5)	10.6 (4)	5.6 (5)	0.002*
VAS for general global health, part of the EQ-5D-3 L (0–100 mm) (mean, SD)	62.4 (16)	57.3 (14)	65.8 (27)	0.092
ESR⁺ (mm/hr) (median, IQR)	27.5 (25)	27.5 (25)	25 (25)	0.56
CRP⁺ (mg/L) (median, IQR)	8 (9)	6 (9)	9.5 (14)	0.78
SJC-66 (median, IQR)	0 (8)	8 (19)	0 (2)	0.03*
TJC-68 (median, IQR)	0.5 (9)	12 (19)	0 (2)	0.01*
SJC - foot and ankle (median, IQR)	0 (3)	2 (10)	0 (1)	0.006*
TJC - foot and ankle (median, IQR)	0 (4)	3 (11)	0 (1)	0.001*

* Significant p value found (p < 0.05), ⁺ missing data
MD-HAQ multi-dimensional Health Assessment Questionnaire, VAS visual analogue scale, NRS numerical rating scale, RAPID3 Routine Assessment of Patient Index Data 3, ESR erythrocyte sedimentation rate, CRP c-reactive protein, EQ-5D-3 L European-QoL 5-dimensional level-3 questionnaire, SJC-66 swollen joint count 66, TJC-68 tender joint count 68, IQR interquartile range, SD standard deviation

ISSN: 2520-1026